105 related articles for article (PubMed ID: 21194777)
1. Contrasting cardiovascular risk profiles and prescribed cardio-protective therapies in newly-diagnosed type 2 diabetes identified through screening and standard practice.
Webb DR; Gray LJ; Khunti K; Campbell S; Dallosso H; Davies MJ
Diabetes Res Clin Pract; 2011 Mar; 91(3):280-5. PubMed ID: 21194777
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care.
Teoh H; Després JP; Dufour R; Fitchett DH; Goldin L; Goodman SG; Harris SB; Langer A; Lau DC; Lonn EM; Mancini GB; McFarlane PA; Poirier P; Rabasa-Lhoret R; Tan MK; Leiter LA
Diabetes Obes Metab; 2013 Dec; 15(12):1093-100. PubMed ID: 23683111
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of cardiovascular disease in type 2 diabetic patients].
Yokota C
Nihon Rinsho; 2003 Jul; 61(7):1161-6. PubMed ID: 12877078
[TBL] [Abstract][Full Text] [Related]
4. Introductory remarks.
Velasco M; Bermúdez V; Israili ZH; Hernández-Hernández R
Am J Ther; 2010; 17(3):236. PubMed ID: 20479578
[No Abstract] [Full Text] [Related]
5. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Reiner Z; Keil U;
Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):530-40. PubMed ID: 20577089
[TBL] [Abstract][Full Text] [Related]
6. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
7. The significance of plasma adrenomedullin and calcitonin gene-related peptide concentration in patients with Type 2 diabetes mellitus who are treated for cardiovascular risk factors.
Charvat J; Svab P; Havlin J; Bilek R; Zamrazil V
Neuro Endocrinol Lett; 2014; 35(2):154-8. PubMed ID: 24878981
[TBL] [Abstract][Full Text] [Related]
8. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
Basile J; Houston M; Ferrario CM
J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
[No Abstract] [Full Text] [Related]
9. [Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)].
Wiersma T; Smulders YM; Stehouwer CD; Konings KT; Lanphen J
Ned Tijdschr Geneeskd; 2012; 156(36):A5104. PubMed ID: 22951134
[TBL] [Abstract][Full Text] [Related]
10. Fish oils for cardiovascular disease: Impact on diabetes.
Rudkowska I
Maturitas; 2010 Sep; 67(1):25-8. PubMed ID: 20493648
[TBL] [Abstract][Full Text] [Related]
11. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Mazzone T
Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
[TBL] [Abstract][Full Text] [Related]
12. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.
Mazzaglia G; Ambrosioni E; Alacqua M; Filippi A; Sessa E; Immordino V; Borghi C; Brignoli O; Caputi AP; Cricelli C; Mantovani LG
Circulation; 2009 Oct; 120(16):1598-605. PubMed ID: 19805653
[TBL] [Abstract][Full Text] [Related]
13. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?
Tomlinson J; Millward A; Stenhouse E; Pinkney J
Diabet Med; 2010 May; 27(5):498-515. PubMed ID: 20536945
[TBL] [Abstract][Full Text] [Related]
14. ACCORD and Risk-Factor Control in Type 2 Diabetes.
Nilsson PM
N Engl J Med; 2010 Apr; 362(17):1628-30. PubMed ID: 20228405
[No Abstract] [Full Text] [Related]
15. The effect of hyperglycemia and its therapies on the heart.
Wyne KL
Heart Fail Clin; 2006 Jan; 2(1):61-70. PubMed ID: 17386877
[No Abstract] [Full Text] [Related]
16. Management of diabetes in cardiovascular patients: diabetic heart disease.
Peter R; Cox A; Evans M
Heart; 2008 Mar; 94(3):369-75. PubMed ID: 18276822
[No Abstract] [Full Text] [Related]
17. [Diabetes, hypertension and microalbuminuria in primary care].
Bramlage P; Wittchen HU; Pittrow D; Dikow R; Kirch W; Lehnert H; Ritz E
Fortschr Med Orig; 2003 Feb; 121 Suppl 1():33-8. PubMed ID: 14732948
[TBL] [Abstract][Full Text] [Related]
18. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
[No Abstract] [Full Text] [Related]
19. Attenuating cardiovascular risk factors in patients with type 2 diabetes.
Garber AJ
Am Fam Physician; 2000 Dec; 62(12):2633-42, 2645-6. PubMed ID: 11142470
[TBL] [Abstract][Full Text] [Related]
20. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
